Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
暂无分享，去创建一个
H. Gray | G. Fleming | Lainie P. Martin | W. Munasinghe | H. Xiong | M. Cristea | K. Bell-McGuinn | D. Sullivan | Yan Luo | M. McKee | Lainie P Martin